NASDAQ:TORC - resTORbio Stock Price, Forecast & News

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.14. View resTORbio's Earnings History.

resTORbio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for resTORbio.

4 brokerages have issued 1-year target prices for resTORbio's shares. Their forecasts range from $3.00 to $28.00. On average, they anticipate resTORbio's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 947.3% from the stock's current price. View Analyst Price Targets for resTORbio.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for resTORbio.

News articles about TORC stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. resTORbio earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for resTORbio.

resTORbio saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,240,000 shares, a drop of 8.1% from the December 15th total of 1,350,000 shares. Based on an average trading volume of 1,750,000 shares, the days-to-cover ratio is currently 0.7 days. Currently, 4.4% of the shares of the company are sold short. View resTORbio's Current Options Chain.

Some companies that are related to resTORbio include LifeVantage (LFVN), Cerecor (CERC), Tyme Technologies (TYME), XOMA (XOMA), Theratechnologies (THTX), GlycoMimetics (GLYC), Obseva (OBSV), Bicycle Therapeutics (BCYC), Protagonist Therapeutics (PTGX), Athersys (ATHX), Chiasma (CHMA), IDEAYA Biosciences (IDYA), Arbutus Biopharma (ABUS), Fortress Biotech (FBIO) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include Novavax (NVAX), Viking Therapeutics (VKTX), vTv Therapeutics (VTVT), ADMA Biologics (ADMA), Catalyst Pharmaceuticals (CPRX), Cytokinetics (CYTK), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), IQIYI (IQ) and Opko Health (OPK).

(TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

resTORbio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Brave Asset Management Inc. (0.06%). Company insiders that own resTORbio stock include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.

TORC stock was purchased by a variety of institutional investors in the last quarter, including Brave Asset Management Inc.. Company insiders that have bought resTORbio stock in the last two years include Chen Schor, Orbimed Advisors Llc and Puretech Health Llc. View Insider Buying and Selling for resTORbio.

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TORC stock can currently be purchased for approximately $1.48.

resTORbio has a market capitalization of $53.93 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About resTORbio.

The official website for resTORbio is http://www.restorbio.com/.

resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528.